OptimizeRx Corporation reiterated earnings guidance for the year 2022. For the period, the company is reiterating its full year financial outlook for 2022 for net revenue to be between $62 million and $68 million, representing year-over-year growth of 1% to 11%, respectively, and gross margins to be between 59% and 62%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.66 USD | -2.16% | -3.21% | -11.53% |
14/05 | Transcript : OptimizeRx Corporation, Q1 2024 Earnings Call, May 14, 2024 | |
14/05 | OptimizeRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.53% | 236M | |
+29.50% | 448B | |
+33.30% | 279B | |
+3.17% | 134B | |
+28.11% | 93.43B | |
+7.98% | 91.72B | |
+65.13% | 61.12B | |
+13.70% | 46.14B | |
+22.96% | 37.49B | |
-4.73% | 35.1B |
- Stock Market
- Equities
- OPRX Stock
- News OptimizeRx Corporation
- OptimizeRx Corporation Reiterates Earnings Guidance for the Year 2022